Trading at a discount compared to peers, but the underlying intrinsic cash flows struggle to support the current price.
Moderate quality score of 52/100, reflecting stable operating margins and manageable leverage.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Confirm your valuation thesis with live pattern overlays, key pivot levels, and AI trade plans.
Verdict: Average quality business weighed down by significant growth concerns.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. This outlook is strongly supported by highly attractive capital returns, anchored by a strong dividend yield, though free cash flow coverage appears tight.
SOLS demonstrates strong business quality with robust profitability and healthy margins. This is paired with a moderately leveraged but stable balance sheet.
The company maintains stable top-line performance paired with stable bottom-line earnings. The company maintains healthy operational efficiency with a 17.7% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $986.0M | +6.5% | — | — | — | |
| EBITDA | $253.0M | — | — | — | — | |
| Net Income | $80.0M | -43.8% | — | — | — | |
| EPS (Diluted) | $0.50 | -44.0% | — | — | — | |
| Free Cash Flow | $446.0M | -81.1% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 31.9% | 34.5% | 34.5% | 34.5% |
| Operating Margin | 17.7% | 20.9% | 20.9% | 20.9% |
| Net Margin | 8.1% | 11.6% | 11.6% | 11.6% |
| FCF Margin | 18.7% | 10.1% | 10.1% | 10.1% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q4'26Latest | $0.70 | $0.80 | +14.8% | ||
| Q3'26 | $0.77 | $0.88 | +13.7% | ||
| Q2'26 | $0.61 | $0.63 | +2.6% | ||
| Q1'26 | $0.40 | $0.26 | -35.0% | ||
| Q4'25 | $0.54 | $0.53 | -1.3% |
Total return is +58.9% (1Y), outperforming the benchmark by +48.2%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +33.6% | +26.7% | — |
| 1Y | +58.9% | +48.2% | +0.5% |
| 3YCAGR | +10.8% | -7.4% | +0.5% |
| 5YCAGR | +6.3% | -3.5% | +0.5% |
| 10YCAGR | +3.1% | -10.0% | — |
The S&P 500 is at 22.0x trailing P/E — Fair relative to historical averages.
Quick answers to common questions about Solstice Advanced Materials Inc. (SOLS) valuation, health, and returns.
Solstice Advanced Materials Inc. is estimated to be overvalued under our discounted cash flow framework. relative multiples indicate the stock is Slightly cheap versus peers compared to industry peers. overvalued (implying -64.5% downside from DCF intrinsic value of $23.49)
Solstice Advanced Materials Inc. has multiple valuation anchors: DCF Intrinsic Value: $23.49 | Peer Relative Fair Value: $75.14 | Wall Street Analyst Target: $78.67 (implying +19.9% upside). A convergence of these signals offers higher conviction.
Solstice Advanced Materials Inc. displays fair financial health with a composite quality score of 52/100, supported by a Piotroski F-Score of 3/9, Return on Invested Capital (ROIC) of 14.8%.
Solstice Advanced Materials Inc. pays a 14.4% dividend yield, covered by a 633% payout ratio with 0 years of growth, supplemented by a 0.0% buyback yield.
Solstice Advanced Materials Inc.'s current growth trajectory is Stable. The company achieved +6.5% 1Y revenue growth and -44.0% 1Y EPS growth, compared to its 3Y revenue CAGR of N/A.
Wall Street consensus is Buy based on 5 analysts, beating EPS expectations in 60% of recent quarters with a 3-quarter streak. The consensus price target represents a +19.9% change from current levels.
Investment risks for Solstice Advanced Materials Inc. include: -37.9% 1-year max drawdown, high beta (1.52x market volatility), stretched payout ratio. Volatility risk is characterized by a beta of 1.52x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.